Advances in endocrine therapy of breast cancer: proceedings of the 2003 Gleneagles Conference

Because of the predominant role estrogens play in the development of breast cancer and the limited effectiveness of tamoxifen therapy, more selective therapeutics targeting estrogen signaling have been developed: selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and a third generation of drugs that inhibit the aromatase required for estrogen biosyntheses.

The authors examine clinical and translational research results from studies of these endocrine therapies and chemotherapies in pre- and postmenopausal women with early and advanced breast cancer.

Advances in Endocrine Therapy of Breast Cancer provides guidance on promising new therapeutics and treatment combinations based on compelling clinical evidence.